CA3069016A1 - Bicyclic urea kinase inhibitors and uses thereof - Google Patents

Bicyclic urea kinase inhibitors and uses thereof Download PDF

Info

Publication number
CA3069016A1
CA3069016A1 CA3069016A CA3069016A CA3069016A1 CA 3069016 A1 CA3069016 A1 CA 3069016A1 CA 3069016 A CA3069016 A CA 3069016A CA 3069016 A CA3069016 A CA 3069016A CA 3069016 A1 CA3069016 A1 CA 3069016A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
alkyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069016A
Other languages
English (en)
French (fr)
Inventor
Nathanael S. Gray
Yanke LIANG
Hwan Geun Choi
Thomas Sundberg
Alykhan SHAMJI
Ramnik Xavier
David E. Fisher
Nisma MUJAHID
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc, Broad Institute Inc filed Critical General Hospital Corp
Publication of CA3069016A1 publication Critical patent/CA3069016A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3069016A 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof Pending CA3069016A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662358524P 2016-07-05 2016-07-05
US62/358,524 2016-07-05
PCT/US2017/040722 WO2018009544A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3069016A1 true CA3069016A1 (en) 2018-01-11

Family

ID=59351134

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069016A Pending CA3069016A1 (en) 2016-07-05 2017-07-05 Bicyclic urea kinase inhibitors and uses thereof

Country Status (10)

Country Link
US (3) US10954242B2 (enExample)
EP (2) EP3481830B1 (enExample)
JP (1) JP7277357B2 (enExample)
KR (1) KR20190075043A (enExample)
CN (1) CN110225914A (enExample)
AU (1) AU2017291812B2 (enExample)
CA (1) CA3069016A1 (enExample)
ES (1) ES2920823T3 (enExample)
IL (1) IL264106B (enExample)
WO (1) WO2018009544A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3171874B1 (en) 2014-07-21 2020-11-18 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
JP7277357B2 (ja) 2016-07-05 2023-05-18 ザ ブロード インスティテュート，インコーポレーテッド 二環式尿素キナーゼインヒビターおよびそれらの使用
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
EP3589284A4 (en) 2017-02-28 2020-12-16 The General Hospital Corporation USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS
PL3774805T3 (pl) * 2018-03-30 2024-05-06 Les Laboratoires Servier Heterobicykliczne inhibitory mat2a i sposoby przydatne do leczenia nowotworu
WO2020027200A1 (ja) * 2018-08-01 2020-02-06 小野薬品工業株式会社 軟骨関連疾患治療剤
WO2021062327A1 (en) * 2019-09-27 2021-04-01 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
CA3169649A1 (en) * 2020-01-30 2021-08-05 The Regents Of The University Of California Strad-binding agents and uses thereof
EP4143191A2 (en) * 2020-04-28 2023-03-08 iOmx Therapeutics AG Bicyclic kinase inhibitors and uses thereof
EP4149629B1 (en) 2020-05-14 2025-06-04 Rhizen Pharmaceuticals AG Purine derivatives as sik-3 inhibitors
KR102673031B1 (ko) * 2020-09-16 2024-06-07 주식회사 엑세쏘바이오파마 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물
AU2021343539A1 (en) * 2020-09-21 2023-05-18 Soltego, Inc. Sik inhibitors and methods of use thereof
CN116801878A (zh) * 2020-10-05 2023-09-22 达纳-法伯癌症研究所股份有限公司 Her2的有效和选择性抑制剂
WO2022120132A1 (en) * 2020-12-04 2022-06-09 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
US20240174662A1 (en) * 2021-02-01 2024-05-30 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
KR20230053049A (ko) * 2021-10-13 2023-04-21 서울대학교산학협력단 류마티스 관절염 예방 또는 치료용 약학적 조성물 및 건강기능식품
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
CN117547615B (zh) * 2023-09-26 2024-12-06 首都医科大学宣武医院 一种纳米囊泡及其制备方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
ES2310039T3 (es) 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
NZ510760A (en) 1998-10-23 2003-08-29 F Bicyclic nitrogen heterocycles
US20050202001A1 (en) 2002-04-24 2005-09-15 Han-Mo Koo Enhancement of human epidermal melanogenesis
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US20060094013A1 (en) 2002-08-21 2006-05-04 Hiroshi Takemori Salt-inducible kinases 2 and use thereof
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
CN1717396A (zh) 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
KR100864393B1 (ko) 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 피리미도 화합물
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2533774A1 (en) 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0511978A (pt) 2004-06-10 2008-01-22 Irm Llc compostos e composições como inibidores de proteìnas quinases
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007002096A (es) 2004-08-31 2007-03-29 Hoffmann La Roche Derivados de amida de 3-fenil-dihidropirimido[4,5-d] pirimidinonas, su fabricacion y su uso como agentes farmaceuticos.
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
CA2610598A1 (en) * 2005-06-10 2006-12-21 Irm Llc Compounds that maintain pluripotency of embryonic stem cells
ME00011A (me) 2005-12-21 2009-02-10 Novartis Ag Derivati pirimidinilaril uree kao fgf inhibitori
BRPI0711628A2 (pt) * 2006-05-15 2011-12-06 Irm Llc composto, composição farmacêutica, uso e processo para preparação do composto
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
ES2610190T3 (es) 2007-11-28 2017-04-26 Dana-Farber Cancer Institute, Inc. Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009152027A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
EP2376494A4 (en) * 2008-12-12 2012-07-11 Msd Kk DIHYDROPYRIMIDOPYRIMIDINDERIVATE
CN102656174A (zh) 2009-10-14 2012-09-05 百时美施贵宝公司 用于治疗丙型肝炎的化合物
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
KR20140078710A (ko) 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
SMT201800608T1 (it) 2012-04-24 2019-01-11 Vertex Pharma Inibitori di dna-pk
GB201212960D0 (en) * 2012-07-20 2012-09-05 Common Services Agency Erythroid production
JP5683634B2 (ja) * 2012-11-28 2015-03-11 株式会社ショーワ 圧力緩衝装置
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
CN105209040A (zh) 2013-03-15 2015-12-30 昂科迪塞恩股份有限公司 大环的盐可诱导的激酶抑制剂
AU2014228746B2 (en) * 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASEHEMMER FOR THE TREATMENT OF DISEASES
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
EP3171874B1 (en) 2014-07-21 2020-11-18 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3177295A4 (en) 2014-08-08 2018-06-13 Dana Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
KR101850282B1 (ko) 2014-11-26 2018-05-31 한국과학기술연구원 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
CN104482860B (zh) 2014-12-05 2017-10-31 浙江大学宁波理工学院 鱼类形态参数自动测量装置和方法
JP7277357B2 (ja) 2016-07-05 2023-05-18 ザ ブロード インスティテュート，インコーポレーテッド 二環式尿素キナーゼインヒビターおよびそれらの使用
WO2018053373A1 (en) * 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
EP3589284A4 (en) 2017-02-28 2020-12-16 The General Hospital Corporation USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS

Also Published As

Publication number Publication date
AU2017291812A1 (en) 2019-02-21
EP3481830B1 (en) 2022-02-16
US20190315752A1 (en) 2019-10-17
US11725011B2 (en) 2023-08-15
WO2018009544A1 (en) 2018-01-11
US20210147425A1 (en) 2021-05-20
US12398145B2 (en) 2025-08-26
CN110225914A (zh) 2019-09-10
IL264106B (en) 2022-04-01
US10954242B2 (en) 2021-03-23
EP3481830A1 (en) 2019-05-15
AU2017291812B2 (en) 2023-12-14
EP4047001A2 (en) 2022-08-24
US20200317675A9 (en) 2020-10-08
JP2019527682A (ja) 2019-10-03
ES2920823T3 (es) 2022-08-10
KR20190075043A (ko) 2019-06-28
US20230234959A1 (en) 2023-07-27
JP7277357B2 (ja) 2023-05-18
EP4047001A3 (en) 2022-11-30
IL264106A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
US12398145B2 (en) Bicyclic urea kinase inhibitors and uses thereof
US12209076B2 (en) Imidazolyl kinase inhibitors and uses thereof
CA2954187C (en) Macrocyclic kinase inhibitors and uses thereof
CA2955074A1 (en) Diazepane derivatives and uses thereof
CA2955077A1 (en) Dihydropteridinone derivatives and uses thereof
CA2936871A1 (en) Dihydropteridinone derivatives and uses thereof
HK40070345A (en) Bicyclic urea kinase inhibitors and uses thereof
WO2024259178A1 (en) Glycogen synthase kinase 3 inhibitors and uses thereof
HK40008957B (en) Bicyclic urea kinase inhibitors and uses thereof
EP4601637A2 (en) Glycogen synthase kinase 3 inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406

EEER Examination request

Effective date: 20220406